Drug Database: Tecovirimat

EA-IND protocol

Expanded access investigational new drug (EA-IND) protocol

The Centers for Disease Control and Prevention (CDC) holds an EA-IND protocol that allows for the use of tecovirimat for the treatment of non-variola orthopoxvirus infections, including mpox. To view the protocol, see the following link: Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children (Version 6.5; January 31, 2025)

For the latest information and updates related to the use of tecovirimat for mpox treatment or PEP, please visit the following CDC webpages: Tecovirimat (TPOXX) for Treatment of Monkeypox, Caring for Patients with Monkeypox, and Clinical Considerations for Monkeypox in Immunocompromised People. Recommendations on the use of tecovirimat for treating and preventing mpox in people with HIV are also available from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV.

For additional information about tecovirimat, see the FDA-approved drug label: Injection (solution, concentrate); Capsule